Browsing: Bispecific

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), and Sidewinder…

Register Now Panelists: Shahram Misaghi, PhD Research Fellow, Cell Line DevelopmentProlific Machines View Bio Panelist Shahram Misaghi, PhD Shahram Misaghi,…

Genmab has agreed to acquire Merus for approximately $8 billion, the companies said today, in a deal intended to bolster…